Phase I Study of Pasireotide (SOM230) in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumours.

Trial Profile

Phase I Study of Pasireotide (SOM230) in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumours.

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Oct 2016

At a glance

  • Drugs Everolimus (Primary) ; Pasireotide (Primary) ; Pasireotide (Primary)
  • Indications Neuroendocrine carcinoma
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 12 Apr 2016 Planned End Date changed from 1 Oct 2014 to 1 Oct 2016.
    • 28 Apr 2014 Planned End Date changed from 1 Oct 2013 to 1 Oct 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top